Chai Discovery Secures $70M to Revolutionize Drug Design
Slice of Healthcare Team
08/14/2025
Key highlights
- $70M Series A led by Menlo Ventures with major AI and biotech investors.
- Launch of Chai-2, achieving ~20% hit rate in de novo antibody design.
- Former Pfizer CSO Mikael Dolsten joins board of directors.
Source: Business Wire
Notable Quotes
“ Progress towards game-changing drugs and treatments is far too slow… Chai Discovery exists to push the boundaries… so that breakthroughs can be designed rather than simply discovered. ”
Joshua Meier, CEO & Co-founder at Chai Discovery
“ I’m proud to join Chai Discovery and redefine biology from science into engineering. ”
Mikael Dolsten, M.D., PhD., Former CSO at Pfizer
“ Before Chai-2… a company had spent more than three years and over $5m on a problem. With Chai-2, we… found an experimentally validated solution within two weeks. ”
Matthew McPartlon, Co-founder at Chai Discovery
Why This Matters
This funding marks a significant milestone in the fusion of AI and biotechnology. Chai Discovery’s AI models, especially Chai-2, are breaking through long-standing barriers in drug discovery by dramatically improving success rates and reducing timelines for antibody design. By enabling scientists to engineer therapeutics from scratch with unprecedented precision, Chai Discovery could accelerate the arrival of treatments for diseases that have eluded conventional research, reshaping the future of medicine.
